COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients

Depression Clinical Trial

Official title:

COVID19 and Psychological Health: a Cross Sectional Evaluation of the Risks of Anxiety and Depression Among Patients Diagnosed With Covid 19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04689464
• Other study ID #: 1120
• Status: Completed
• Start date: December 1, 2020
• Est. completion date: June 1, 2021

Study information

• Verified date: June 2021
• Source: AlFayhaa General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The covid-19 pandemic started to spread worldwide since December 2019. It promoted to an exaggerated psychological stress and anxiety in humans due to the intolerable symptoms higher than usual death of many infected patients. This study examines the corona related anxiety and if there is need for drug intervention to treat this anxiety.

To answer these questions, a survey made to the hospitalized patients including sex, age, educational level, Marital state, and a standardized questionnaires (GAD-7 and PHQ-9) which has been validated and shown to possess good psychometric qualities in studies of participants from multiple populations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 450
• Est. completion date: June 1, 2021
• Est. primary completion date: May 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• patients with COVID19 willing to participate in the study

Exclusion Criteria:

• unwilling unable to read or interact with standardized questionnaire unconscious

Related Conditions & MeSH terms

• Anxiety
• Anxiety Disorders
• Covid19
• Depression
• Depressive Disorder

Locations

Country	Name	City	State
Iraq	AlFayhaa Teaching hospital	Basra

Sponsors (3)

Lead Sponsor	Collaborator
Alhasan Mujtaba Al-Mudhaffer	Ministry of Health, Iraq, University of Basrah

Country where clinical trial is conducted

Iraq, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	depression	Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; >20 severe. Minimum 0 maximum 27 points	at the time of acute infection, average of 1 month
Primary	anxiety	Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; >15 severe. Minimum 0, maximum 21 points	at the time of acute infection, average of 1 month